LSV Asset Management Grows Position in Biogen Inc. $BIIB

LSV Asset Management raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 21.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 306,839 shares of the biotechnology company’s stock after acquiring an additional 54,880 shares during the period. LSV Asset Management owned about 0.21% of Biogen worth $42,982,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Biogen by 1.5% during the second quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock worth $2,171,533,000 after purchasing an additional 257,812 shares during the last quarter. State Street Corp lifted its position in shares of Biogen by 1.0% during the 2nd quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after buying an additional 71,897 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Biogen by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company’s stock worth $490,089,000 after buying an additional 71,286 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Biogen by 2.4% in the 2nd quarter. Invesco Ltd. now owns 2,320,126 shares of the biotechnology company’s stock worth $291,385,000 after buying an additional 55,119 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Biogen in the second quarter valued at approximately $284,358,000. Institutional investors own 87.93% of the company’s stock.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is owned by insiders.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $196.52 on Friday. The firm has a market capitalization of $28.84 billion, a PE ratio of 22.31, a P/E/G ratio of 1.55 and a beta of 0.16. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company has a 50-day moving average price of $178.22 and a two-hundred day moving average price of $158.85. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the company posted $3.44 EPS. Biogen’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analyst Weigh In

BIIB has been the topic of several research analyst reports. Jefferies Financial Group boosted their price objective on Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, November 28th. Wolfe Research set a $231.00 target price on Biogen in a research note on Monday. BMO Capital Markets increased their price target on shares of Biogen from $165.00 to $196.00 and gave the company a “market perform” rating in a research report on Friday, February 6th. Royal Bank Of Canada raised their price objective on shares of Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a report on Monday, February 9th. Finally, Piper Sandler lifted their price objective on shares of Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Biogen has a consensus rating of “Hold” and an average target price of $205.84.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.